Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$10.60M$10.60Mderived+67.2% vs Q4 2021 Net Income-$28.49M-$28.49MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$9,257,000N/M Operating Cash Flowderived-$21,843,000N/M Free Cash Flowderived-$22,475,000N/M Margins · derivedOperating margin87.3%+572.0 pt vs Q4 2021
Net margin-268.8%+82.8 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 9, 2023 · 68 d after period end